UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

<u>April 21, 2010</u> (Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Exact Name of I	Registrant as Specified in	its Charter)
DELAWARE	1-11353	13-3757370
(State or other jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)
358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA	27215	336-229-1127
(Address of principal executive offices)	(Zip Code)	(Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. Regulation FD Disclosure

Summary information of the Company dated April 21, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

<u>Laboratory Corporation of America Holdings</u> (Registrant)

Date: April 21, 2010

By: /s/F. Samuel Eberts III F. Samuel Eberts III, Chief Legal Officer and Secretary





This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors.

Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect the Company's financial results will be included in the Company's Form 10-K for the year ended December 31, 2009, and subsequent SEC filings. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change.



	Thr	ee Months		
		2010	2009	+/(-)
Revenue	\$	1,193.6	\$ 1,155.7	3.3%
Adjusted Operating Income ⁽¹⁾	\$	243.5	\$ 240.5	1.2%
Adjusted Operating Income Margin ⁽¹⁾		20.4%	20.8%	(40) bp
Adjusted EPS ⁽¹⁾	\$	1.30	\$ 1.22	6.6%
Operating Cash Flow	\$	232.0	\$ 208.9	11.1%
Less: Capital Expenditures	\$	(24.5)	\$ (30.7)	(20.2%)
Free Cash Flow	\$	207.5	\$ 178.2	16.4%


(1) See Reconciliation of non-GAAP Financial Measures (included herein)






Cash Flow Trends


11% FCF CAGR 2004-2009



4


LabCorp







Revenue by Business Area - US 2010 YTD



6



	YTD Q1-2008					YTD Q1-2009				YTD Q1-2010						
	Revenue						Revenue		a.		3	Revenu	ie	6		
	\$'s	%	Accns		PPA		\$'s	%	Accns	PPA		\$'s	%	Accns	I	PPA
Client	\$ 285.4	27%	8.638	\$	33.04	\$	303.3	28%	8.918	\$ 34.01	\$	307.9	27%	8.598	\$	35.80
Patient	97.9	9%	0.590	\$	165.98		83.7	8%	0.531	\$157.57		88.3	8%	0.536	\$1	164.81
Third Party																
(Medicare/Medicaid)	198.8	19%	4.728	\$	42.05		220.3	20%	4.983	\$ 44.21		228.5	20%	4.927	\$	46.37
Managed Care:																
- Capitated	42.4	4%	3.691	\$	11.49		44.6	4%	3.665	\$ 12.16		39.0	3%	3.225	\$	12.11
- Fee for service	414.6	40%	9.339	\$	44.39		448.3	41%	9.584	\$ 46.78		461.0	41%	9.491	\$	48.57
Total Managed Care	457.0	44%	13.030	\$	35.07		492.9	45%	13.249	\$ 37.20	8	500.0	44%	12.716	\$	39.32
LabCorp Total - US	\$ 1,039.1	100%	26.986	\$	38.51	\$	1,100.1	100%	27.681	\$ 39.74	\$	1,124.7	100%	26.777	\$	42.00
LabCorp Total - Canada	\$ 64.1	-	1.835	\$	34.90	\$	55.6	-	2.269	\$ 24.50	\$	68.9	-	2.287	\$	30.14
LabCorp Total	\$ 1,103.2		28.821	\$	38.28	\$	1,155.7		29.950	\$ 38.59	\$	1,193.6		29.064	\$	41.07

7

Revenue by Business Area (in millions, except PPA)

		YTD Q1-2008				YTD Q1-2009					YTD Q1-2010							
	_	Revenue				Revenue				Revenue								
	_	\$'s	%	Accns	_	PPA	_	\$'s	%	Accns	_	PPA		\$'s	%	Accns		PPA
All Genomic	\$	156.4	15%	2.144	\$	72.94	\$	172.4	16%	2.250	\$	76.64	\$	174.5	16%	2.189	\$	79.68
Other Esoteric		118.1	11%	2.881		40.98		140.2	13%	3.303		42.44		161.8	14%	3.734		43.33
Histology		79.2	8%	0.629		125.99		73.5	7%	0.609		120.69		70.1	6%	0.564		124.28
All Genomic / Esoteric		353.7	34%	5.654		62.55	1	386.1	35%	6.162		62.67	12. 	406.4	36%	6.487		62.65
Core	1.0	685.5	66%	21.332		32.13		714.0	65%	21.520		33.18	19	718.3	64%	20.290		35.40
LabCorp Total - US	\$	1,039.1	100%	26.986	\$	38.51	\$	1,100.1	100%	27.681		39.74	\$	1,124.7	100%	26.777		42.00
LabCorp Total - Canada	\$	64.1	-	1.835	\$	34.90	\$	55.6	-	2.269	\$	24.50	\$	68.9	-	2.287	\$	30.14
LabCorp Total	\$	1,103.2		28.821	\$	38.28	\$	1,155.7		29.950	\$	38.59	\$	1,193.6		29.064	\$	41.07

8



Excluding the impact of restructuring and other special charges and share repurchase activity after March 31, 2010, guidance for 2010 is:

Revenue growth:	Approximately 2.5% – 4.5%
Adjusted EPS:	\$5.35 to \$5.55
• Operating cash flow of approximately ⁽¹⁾ :	\$870 Million
Capital expenditures of approximately:	\$135 Million

(1) Operating cash flow guidance excludes any transition payments to UnitedHealthcare.



Laboratory Corporation of America Other Financial Information March 31, 2010 (\$ in millions)

	Q1 10
Depreciation	\$32.2
Amortization	\$17.4
Capital expenditures	\$24.5
Cash flows from operations	\$232.0
Bad debt as a percentage of sales	5.05%
Effective interest rates on debt:	
Zero-coupon subordinated notes	2.00%
5 1/2% Senior Notes	5.38%
5 5/8% Senior Notes	5.75%
Term loan	3.67%
Revolving credit facility (weighted average)	0.58%
Days sales outstanding	46
UnitedHeathcare transition payments - Billed	\$10.1
UnitedHeathcare transition payments - Paid	\$14.5



Reconciliation of non-GAAP Financial Measures

(In millions, except per share data)

	Three Months E	nded Mar 31,
Adjusted Operating Income	2010	2009
Operating income	\$234.2	\$240.5
Restructuring and other special charges	9.3	
Adjusted operating income	\$243.5	\$240.5
Adjusted EPS		
Diluted earnings per common share	\$1.25	\$1.22
Impact of restructuring and other special charges (1)	0.05	
Adjusted EPS	\$1.30	\$1.22

(1) After tax impact of restructuring and other special charges, \$5.7 million divided by 106.5 million shares



LabCorp

